Neuralstem announces plans for public offering of stock, warrants

Proceeds will fund regulatory, pre-clinical and clinical activities

By Angela McDaniels

Tacoma, Wash., May 2 – Neuralstem, Inc. intends to offer common stock and warrants in an underwritten public offering. Roth Capital Partners is the bookrunner, and Brean Capital is co-manager.

The shares of common stock and warrants will be immediately separable and will be issued separately, according to a company news release.

The company plans to use the proceeds to fund regulatory, pre-clinical and clinical activities and general corporate purposes, including working capital and the repayment of debt.

Neuralstem is a Germantown, Md.-based biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.